期刊文献+

血液病患者细菌性血流感染病原菌分布及耐药特点单中心数据分析

A single-center analysis of pathogenic bacteria distribution and drug resistance in bacterial bloodstream infections among patients with hematological diseases
原文传递
导出
摘要 目的分析血液病患者细菌性血流感染的病原菌分布和耐药情况, 为临床经验性抗感染治疗提供病原学数据依据。方法对天津医科大学总医院血液科2016年1月至2022年12月经血培养确诊为细菌性血流感染的血液病患者的一般临床信息、病原菌及药物敏感试验结果进行回顾性分析。结果共纳入498例细菌性血流感染患者, 共发生619例次感染, 分离出639株细菌。其中86.9%为恶性血液病患者, 76.7%处于粒细胞缺乏期, 65.9%存在导管留置, 32.6%出现降钙素原升高, 10.7%发生血流动力学改变。常见感染部位为呼吸道(60.6%)、口腔黏膜及皮肤软组织(17.3%)、腹腔(14.5%)。639株细菌中革兰阴性(G-)菌占79.0%, 革兰阳性(G+)菌占21.0%, 前5位病原菌依次为肺炎克雷伯菌(22.5%)、大肠埃希菌(20.8%)、铜绿假单胞菌(15.0%)、屎肠球菌(5.5%)、嗜麦芽窄食单胞菌(5.0%)。G+球菌检出率在2020-2022年呈上升趋势。肺炎克雷伯菌对喹诺酮类和头孢菌素类药物的耐药率在2016-2018年间有所上升, 但在2019年后呈下降趋势。铜绿假单胞菌对碳青霉烯类药物的耐药率约为20.0%, 2019年耐药率峰值为35.7%。耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)对甲氧西林的耐药率为60.0%, 检测到1例耐利奈唑胺的MRCNS。结论本中心细菌性血流感染以G-杆菌为主, 但G+球菌在2020-2022年呈上升趋势, 应警惕碳青霉烯类耐药铜绿假单胞菌和肺炎克雷伯菌。 Objective To analyze the distribution and drug resistance of pathogens of bacterial bloodstream infection in patients with hematological diseases in the Department of Hematology of Tianjin Medical University General Hospital,and to provide etiological data for clinical empirical anti-infection treatment.Methods A retrospective analysis was conducted on the general clinical information,pathogenic bacteria and drug susceptibility test results of patients with hematological diseases diagnosed with bacterial bloodstream infection by menstrual blood culture in our center from January 2016 to December 2022.Results Patients included 498 inpatients,with a total of 639 bacterial strains.Among the patients,86.9%patients had malignancies,and 76.7%had agranulocytosis.Symptoms of concurrent infections,including those of the respiratory tract,oral mucosa,skin and soft tissues,and abdominal sources were observed in 68.3%patients.Gram-negative bacteria(G)accounted for 79.0%of the isolated bacteria,and gram-positive bacteria (G') accounted for 21.0%. The top five isolated pathogens were Klebsiellapneumoniae (22.5%), Escherichia coli(20.8%), Pseudomonas aeruginosa (15.0%), Enterococcus faecium(5.5%), and Stenotrophomonas maltophilum (5.0%). Escherichia coli exhibited a decreasing trend ofresistance to quinolones, cephalosporins, and carbapenems. Klebsiella pneumoniae exhibited increasingrates of resistance to quinolones and cephalosporins between 2016 and 2018, but the rated decreased after2019. The resistance rate to carbapenems exhibited by Pseudomonas aeruginosa was approximately 20%.Carbapenem-resistant strains of Pseudomonas aeruginosa strains were first detected in 2017, with a peakresistance rate of 35.7%, detected in 2019. A 60.0% resistance rate to methicillin was observed inmethicillin-resistant coagulase-negative staphylococci (MRCNS), and one case of linezolid-resistantMRCNS was detected. Conclusions Pathogenic bacteria of bacterial bloodstream infections were widelydistributed in our center, and precautions are warranted against carbapenem resistant P. aeruginosa andKlebsiella pneumoniae.
作者 车梦婷 王超盟 孔海芳 刘惠 李丽娟 宋嘉 王化泉 吴玉红 王国锦 关晶 瞿文 邢莉民 刘鸿 王晓明 胡志东 邵宗鸿 付蓉 Che Mengting;Wang Chaomeng;Liu Hui;Kong Haifang;Li Lijuan;Song Jia;Wang Huaquan;Wang Guojin;Wu Yuhong;Guan Jing;Xing Limin;Qu Wen;Liu Hong;Wang Xiaoming;Hu Zhidong;Shao Zonghong;Fu Rong(Department of Hematology,Tianjin Medical University General Hospital,Tianjin 300052,China;Department of Clinical Laboratory,Tianjin Medical University General Hospital,Tianjin 300052,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2024年第10期937-943,共7页 Chinese Journal of Hematology
基金 国家自然科学基金(82270142、82000128、82000129、81900131) 天津市科技支持重点项目(20YFZCSY00060) 天津市医学重点学科(专科)建设项目(TJYXZDXK-028A) 天津市卫生健康委员会青年项目(TJWJ2021QN001、TJWJ2023XK003)。
关键词 血流感染 细菌分布 耐药性 血液系统疾病 Bloodstream infections Bacteria distribution Drug resistance Hematological diseases
  • 相关文献

参考文献6

二级参考文献163

  • 1Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
  • 2Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
  • 3Wiedermann FJ,Kaneider N,Egger P, et al. Migration of human monocytes in response to procalcitonin [J]. Crit Care Med, 2002 , 30(5): 1112-1117.
  • 4Hoffmann G, Totzke G, Seibel M, et al. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin [J]. Crit Care Med, 2001, 29 (1): 112-126.
  • 5Morgenthaler NG, Struck J, Chancerelle Y,et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection [J]. Horm Metab Res, 2003 , 35 ( 5): 290-295.
  • 6Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin- influence of temperature,storage,anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations [J]. EurJ Clin Chem Clin Biochem, 1997 , 35 ( 8): 597-601.
  • 7Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J]. Ann Emerg Med, 2008 , 52 (1): 48-58.
  • 8Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31 (2): 349-355.
  • 9Hirakata Y,Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2008 , 61 (2): 170-174.
  • 10Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department : an observational study[J]. Crit Care, 2(XM, 8 (1): R12-20.

共引文献908

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部